Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide

2026-02-26 14:04:32 ET

The last time I spoke about Ironwood Pharmaceuticals ( IRWD ), it was with respect to a Seeking Alpha article entitled " Ironwood Pharmaceuticals: Q3 of 2024 Data Readout For PBC ." With respect to this article, I mentioned a huge opportunity that the company had where it had the potential to exercise its option for exclusive access to a drug known as CNP-104 for the treatment of patients with primary biliary cholangitis [PBC]. I had given the stock a "Buy" rating on this potential, along with sales of LINZESS [linaclotide] increasing. Today, I'm downgrading this stock from a "Buy" rating to a "Sell." There are several reasons for doing so at this present time, which I'm about to go over now. The first reason is because the hope was that once Ironwood saw the data of CNP-104 treating patients with PBC, it would like what it saw....

Read the full article on Seeking Alpha

For further details see: